Prior authorization of drugs the enrollee has been prescribed prohibited for at least six months.
HF3869 amends Minnesota’s health insurance prior-authorization law to add a new prohibition on requiring prior authorization for prescription drugs that an enrollee has been taking on an ongoing basis for at least the immediately preceding six months. The bill keeps existing bans on prior authorization for emergency services, certain outpatient mental health and substance use disorder treatment, NCCN-consistent antineoplastic cancer treatment, specified preventive services, pediatric hospice services, and neonatal abstinence program treatment, while clarifying that medication-related prior authorization for some of those categories must still follow existing review and appeal timelines.
The new drug-related prohibition would apply to health benefit plans offered, sold, issued, or renewed on or after January 1, 2026. In practical terms, insurers, utilization review organizations, and claims administrators would be barred from forcing repeat prior authorization for stable, ongoing medications after a six-month use period, which could reduce administrative burdens and treatment interruptions for patients and prescribers. The bill amends Minnesota Statutes section 62M.07, subdivision 2, which governs services exempt from prior authorization.
The bill would directly amend Minnesota Statutes 2024, section 62M.07, subdivision 2, expanding the list of services and treatments exempt from prior authorization. It would affect health plan companies, utilization review organizations, and claims administrators by limiting their ability to require prior authorization for certain categories of care, especially ongoing prescription drugs used for at least six months. The change would apply prospectively to health benefit plans renewed or issued on or after January 1, 2026.
Based on the bill text and available context, the measure appears to have a consumer- and patient-protection orientation, aimed at reducing barriers to access for stable, ongoing treatment. The authorship suggests support from multiple legislators, and the bill was referred to the House Commerce Finance and Policy Committee. No committee transcript or vote record is available here, so there is no documented opposition or floor debate in the provided materials.
The main policy tension is between patient access and insurer utilization management. Supporters would likely favor eliminating repeated prior authorization for medications that patients have already been taking successfully for six months, arguing it reduces delays and administrative burden. Potential opponents, typically insurers or managed-care interests, may be concerned that the restriction limits cost-control tools and could reduce oversight of prescribing patterns. The bill also preserves prior authorization for some medication-related services under existing expedited review and appeal procedures, indicating an attempt to balance access with continued utilization review.